Israeli commercial stage biopharmaceutical company BioLineRx Ltd (NASDAQ: BLRX) (TASE: BLRX) announced on Thursday that it has signed a licence agreement with Ayrmid Ltd, the UK-based parent company of Gamida Cell Ltd.

This agreement covers motixafortide (commercially sold in the United States as APHEXDA), BioLineRx's FDA-approved stem cell mobilisation agent indicated in combination with filgrastim (G-CSF) for collection and subsequent autologous transplantation in patients with multiple myeloma.

Under the terms of the agreement, BioLineRx grants Ayrmid an exclusive licence to develop and commercialise APHEXDA (motixafortide) across all indications, excluding solid tumour indications, and in all territories other than Asia. In exchange, BioLineRx will receive a USD10m upfront payment and is also eligible to receive up to an additional USD87m of potential commercial milestones, and royalties ranging from 18% to 23% on net sales of APHEXDA.

Ayrmid will add APHEXDA to its commercial portfolio, which also includes Gamida Cell's OMISIRGE, the first and only FDA-approved, nicotinamide (NAM)-modified cell therapy for patients with haematologic malignancies in need of a stem cell transplant.